Sustained Human Factor VIII Expression in Hemophilia A Mice Following Systemic Delivery of a Gutless Adenoviral Vector

This publication has 47 references indexed in Scilit:

• Adenovirus-Mediated Factor VIII Gene Expression Results in Attenuated Anti-Factor VIII-Specific Immunity in Hemophilia A Mice Compared with Factor VIII Protein Infusion
  Human Gene Therapy, 2001
• Generation and Characterization of E1/E2a/E3/E4-Deficient Adenoviral Vectors Encoding Human Factor VIII
  Molecular Therapy, 2001
• Adenoviral Vector-Mediated Expression of Physiologic Levels of Human Factor VIII in Nonhuman Primates
  Human Gene Therapy, 1999
• Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
  Gene Therapy, 1999
• In Vivo Evaluation of an Adenoviral Vector Encoding Canine Factor VIII: High-Level, Sustained Expression in Hemophiliac Mice
  Human Gene Therapy, 1999
• Adenoviral Gene Therapy Leads to Rapid Induction of Multiple Chemokines and Acute Neutrophil-Dependent Hepatic Injury in Vivo
  Human Gene Therapy, 1999
• Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy
  Gene Therapy, 1997
• High-Level Tissue-Specific Expression of Functional Human Factor VIII in Mice
  Human Gene Therapy, 1996
• Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
  Nature Genetics, 1995
• In VivoGene Delivery and Expression of Physiological Levels of Functional Human Factor VIII in Mice
  Human Gene Therapy, 1995